Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
Total: 92 #1
CompanyShiftPixy, Inc.
IndustryStaffing & Employment Services
Market Cap8.74MEPS (ttm)-133.90
P/E-EPS this Y83.70%
Forward P/E-EPS next Y-
PEG-EPS past 5Y22.10%
P/S0.23EPS next 5Y-
P/B0.05EPS Q/Q-47.20%
Dividend-Sales Q/Q1.10%
Insider Own40.50%Inst Own3.30%
Insider Trans0.00%Inst Trans-99.08%
Short Float0.05%Earnings-
Analyst Recom-Target Price-
Avg Volume73.08K52W Range11.06 - 203.00
Sep-08-22 10:07AMShiftPixy stock soars on record volume, after plan to spin off ShiftPixy Labs business MarketWatch
Sep-08-22 08:00AMShiftPixy Announces Plans to Spin-off ShiftPixy Labs and Dividend its Digital Securities to Shareholders Business Wire
Sep-07-22 08:00AMShiftPixy Announces Application for Dual Listing on Upstream Business Wire
Aug-31-22 12:44PMShiftPixy, Inc. Announces Reverse Stock Split Effective Date Business Wire
May-24-22 04:15PMShiftPixy, Inc. Announces Management Changes Business Wire
May-13-22 07:30AMShiftPixy, Inc. Announces Special Distribution of Shares of Industrial Human Capital, Inc. Business Wire
Mar-18-22 05:00PMShiftPixy, Inc. Announces Revised SPAC Sponsorship Business Wire
Feb-08-22 03:59PMShiftPixy Is Giving Itself Many Ways to Win by Diversifying Its Business InvestorPlace
Feb-01-22 07:00AMCEO Presenting on the Emerging Growth Conference on February 2 Register Now GlobeNewswire
Jan-24-22 02:16PMShort Squeeze Stocks: PIXY, MBOT and 3 Others Experts Think Are Ready to Pop InvestorPlace
ShiftPixy, Inc., together with its subsidiaries, provides staffing solutions in the United States. It offers employment administrative services, such as payroll processing, human resources consulting, and workers' compensation administration and coverage. The Company also operates human resources information systems platform to assist in customer acquisition for the onboarding of new clients into the company's closed proprietary operating and processing information system. It primarily serves restaurant and hospitality service industries. The company was incorporated in 2015 and is headquartered in Miami, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Absher Scott WCEOSep 01Option Exercise195.478,600,0001,681,000,0008,608,125Sep 02 06:38 PM
CompanyAmylyx Pharmaceuticals, Inc.
Market Cap1.36BEPS (ttm)-2.77
P/E-EPS this Y-108.00%
Forward P/E-EPS next Y54.30%
PEG-EPS past 5Y-
P/S4547.20EPS next 5Y-
P/B5.41EPS Q/Q-139.00%
Dividend-Sales Q/Q-
Insider Own9.90%Inst Own55.70%
Insider Trans-0.80%Inst Trans8.18%
Short Float8.32%EarningsAug 11/a
Analyst Recom1.80Target Price30.75
Avg Volume873.85K52W Range6.51 - 33.41
Sep-08-22 10:09AMControversial ALS Drug From Amylyx Gets Rare Second FDA Meeting Bloomberg
Sep-08-22 09:59AMAmylyx ALS drug backed by FDA, malaria vaccine data looks encouraging Yahoo Finance Video
Sep-08-22 09:39AMAmylyx ALS Drug Wins Backing of FDA Advisory Panel. The Stock Spikes. Barrons.com
Sep-07-22 07:45PMAmylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS Business Wire
Sep-07-22 06:59PMAmylyxs ALS Drug Backed by FDA Advisers The Wall Street Journal
Sep-07-22 06:54PMFDA advisors give thumbs-up to ALS drug with major caveat American City Business Journals
Sep-07-22 06:47PMUPDATE 2-Amylyx's ALS drug gets U.S. FDA panel's backing in rare turnaround Reuters
Sep-07-22 10:00AMAmylyx Pharmaceuticals Stock Trading Halted Today Business Wire
Sep-07-22 02:30AMThe FDA Is Giving Amylyx Another Chance on Its ALS Drug. What to Expect. Barrons.com
Sep-06-22 03:12PMFDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate Benzinga
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALS Invest 1 B.V.10% OwnerJul 06Sale20.7060,6091,254,6425,895,280Jul 08 06:44 PM
Cohen Joshua BCo-Chief Executive OfficerMay 05Option Exercise0.37334,520123,7722,898,585May 06 04:05 PM
Klee Justin B.Co-Chief Executive OfficerMay 05Option Exercise0.37334,520123,7722,898,585May 06 04:05 PM
CompanyAsana, Inc.
IndustrySoftware - Application
Market Cap3.55BEPS (ttm)-1.78
P/E-EPS this Y-24.70%
Forward P/E-EPS next Y16.00%
PEG-EPS past 5Y-
P/S8.42EPS next 5Y-
P/B23.22EPS Q/Q-39.30%
Dividend-Sales Q/Q57.20%
Insider Own4.80%Inst Own52.80%
Insider Trans-0.25%Inst Trans-5.14%
Short Float18.10%EarningsSep 07/a
Analyst Recom2.30Target Price34.36
Avg Volume3.03M52W Range16.19 - 145.79
Sep-08-22 09:52AMAsana stock surges on earnings, outlook boost Yahoo Finance Video
Sep-08-22 09:41AMAsana Stock Spikes on Forecast Boost and Share Sale to CEO Barrons.com
Sep-08-22 09:08AMGameStop's Rising, but This Software Stock Is Thursday's Big Winner Motley Fool
Sep-08-22 07:44AMAsana, GameStop, Moderna, Revance, and More Stock Market Movers Thursday Barrons.com
Sep-08-22 05:50AMAsana Stock Spikes on Forecast Boost and Share Sale to CEO Barrons.com
Sep-08-22 03:51AMGameStop, Asana, First Solar Rise Premarket; American Eagle Outfitters Falls Investing.com
Sep-07-22 08:16PMAsana stock rallies more than 20% after beat-and-raise quarter MarketWatch
Sep-07-22 05:25PMAsana, Inc. (ASAN) Reports Q2 Loss, Tops Revenue Estimates Zacks
Sep-07-22 04:30PMEdited Transcript of ASAN.N earnings conference call or presentation 7-Sep-22 8:30pm GMT Thomson Reuters StreetEvents
Sep-07-22 04:05PMAsana Announces Record Second Quarter Fiscal 2023 Revenues Business Wire
Asana, Inc., together with its subsidiaries, operates a work management platform for individuals, team leads, and executives in the United States and internationally. The company's platform enables teams to orchestrate work from daily tasks to cross-functional strategic initiatives; and manages product launches, marketing campaigns, and organization-wide goal settings. It serves customers in industries, such as technology, retail, education, non-profit, government, healthcare, media, and financial services. The company was formerly known as Smiley Abstractions, Inc. and changed its name to Asana, Inc. in July 2009. Asana, Inc. was incorporated in 2008 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wan Tim MChief Financial OfficerJun 22Sale18.203,20358,295609,276Jun 24 07:09 PM
LACEY ELEANOR BGC, Corporate SecretaryJun 22Sale18.201,24922,732170,629Jun 24 06:52 PM
LACEY ELEANOR BGC, Corporate SecretaryMay 04Option Exercise4.024,16716,751169,243May 04 07:50 PM
LACEY ELEANOR BGC, Corporate SecretaryMay 04Sale29.504,167122,926165,076May 04 07:50 PM
LACEY ELEANOR BGC, Corporate SecretaryMay 02Option Exercise4.024,16716,751169,243May 04 07:50 PM
CompanyNutex Health, Inc.
IndustryHealth Information Services
Market Cap2.23BEPS (ttm)-0.14
P/E-EPS this Y68.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y42.20%
P/S15.01EPS next 5Y-
P/B3.91EPS Q/Q56.10%
Dividend-Sales Q/Q994.30%
Insider Own89.10%Inst Own1.10%
Insider Trans0.00%Inst Trans-
Short Float0.90%Earnings-
Analyst Recom-Target Price-
Avg Volume1.28M52W Range2.36 - 52.80
Aug-29-22 06:00AMNutex Health Named 2022 Innovation Award Honoree by The Houston Business Journal PR Newswire
Aug-08-22 08:00AMTraders News Source Senior Editor Mark Roberts Interviews CEO of Nutex Health Tom Vo ACCESSWIRE
Jul-13-22 06:00AMNutex health provides update on growth strategy PR Newswire
Jul-05-22 07:46AMWhat Kind Of Investors Own Most Of Nutex Health, Inc. (NASDAQ:NUTX)? Simply Wall St.
Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.
CompanyShuttle Pharmaceuticals Holdings, Inc.
IndustryDrug Manufacturers - Specialty & Generic
Market Cap483.51MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
Dividend-Sales Q/Q-
Insider Own63.42%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume7.11M52W Range11.77 - 126.26
Sep-06-22 09:00AMShuttle Pharmaceuticals Announces Closing of Initial Public Offering PR Newswire
Aug-31-22 01:20PMShuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH" PR Newswire
Aug-30-22 04:40PMShuttle Pharmaceuticals Announces Pricing of Initial Public Offering PR Newswire
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
CompanyRelay Therapeutics, Inc.
Market Cap2.75BEPS (ttm)-2.59
P/E-EPS this Y-49.40%
Forward P/E-EPS next Y-13.50%
PEG-EPS past 5Y-
P/S1373.08EPS next 5Y-
P/B3.53EPS Q/Q66.40%
Dividend-Sales Q/Q-50.00%
Insider Own0.50%Inst Own-
Insider Trans-28.05%Inst Trans7.32%
Short Float17.35%EarningsAug 04/a
Analyst Recom2.10Target Price39.00
Avg Volume1.08M52W Range12.65 - 38.15
Aug-30-22 11:15AMFor This AI Drug Developer, Look Beyond the Rally TheStreet.com
Aug-25-22 02:48PMRelay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating Investor's Business Daily
Aug-18-22 04:05PMRelay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress GlobeNewswire
Aug-04-22 04:05PMRelay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Jul-28-22 04:05PMRelay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Jun-27-22 06:00AMRelay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event GlobeNewswire
Jun-16-22 07:30AMRelay Therapeutics Announces Timing of Virtual Analyst and Investor Event GlobeNewswire
May-26-22 07:30AMRelay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
May-07-22 09:59AMRelay Therapeutics (NASDAQ:RLAY shareholders incur further losses as stock declines 13% this week, taking one-year losses to 30% Simply Wall St.
May-05-22 04:05PMRelay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bergstrom Donald APresident, R&DSep 02Option Exercise4.124,90020,18894,559Sep 02 05:47 PM
Bergstrom Donald APresident, R&DSep 02Sale25.464,900124,75489,659Sep 02 05:47 PM
Bergstrom Donald APresident, R&DSep 01Option Exercise4.128,10033,37297,759Sep 01 08:26 PM
Bergstrom Donald APresident, R&DSep 01Sale23.078,100186,86789,659Sep 01 08:26 PM
Bergstrom Donald APresident, R&DAug 24Option Exercise4.1215,00061,800104,659Aug 25 05:23 PM
CompanyAeroVironment, Inc.
IndustryAerospace & Defense
Market Cap2.23BEPS (ttm)-0.17
P/E-EPS this Y-117.70%
Forward P/E41.18EPS next Y41.18%
PEG-EPS past 5Y-17.30%
P/S5.01EPS next 5Y18.20%
P/B3.61EPS Q/Q-33.60%
Dividend-Sales Q/Q-2.50%
Insider Own1.00%Inst Own87.70%
Insider Trans-4.30%Inst Trans1.32%
Short Float3.72%EarningsSep 07/a
Analyst Recom2.20Target Price96.33
Avg Volume244.73K52W Range52.03 - 114.11
Sep-08-22 08:06AMAeroVironment (AVAV) Reports Loss in Q1, Sales Improve Y/Y Zacks
Sep-07-22 11:30PMAeroVironment (AVAV) Q1 2023 Earnings Call Transcript Motley Fool
Sep-07-22 05:35PMAeroVironment (AVAV) Reports Q1 Loss, Tops Revenue Estimates Zacks
Sep-07-22 04:30PMEdited Transcript of AVAV.OQ earnings conference call or presentation 7-Sep-22 8:30pm GMT Thomson Reuters StreetEvents
Sep-07-22 04:10PMAeroVironment Announces Fiscal 2023 First Quarter Results Business Wire
Aug-30-22 09:10AMAeroVironments New Mantis i23 D Multi-Sensor Imaging Payload Delivers Superior Daytime Surveillance Performance Business Wire
Aug-26-22 04:19PM7 Growth Stocks With Huge Catalysts Ahead InvestorPlace
Aug-24-22 01:10PMAeroVironment, Inc. Schedules First Quarter Fiscal Year 2023 Earnings Release and Conference Call Business Wire
Aug-23-22 09:10AMAeroVironment Releases Inaugural Corporate Social Responsibility Report Business Wire
Aug-22-22 02:22PMAeroVironment Price Target Bumped Up By 15% At RBC Capital Benzinga
AeroVironment, Inc. designs, develops, produces, delivers, and supports a portfolio of robotic systems and related services for government agencies and businesses in the United States and internationally. It operates through four segments: Unmanned Aircraft Systems (UAS), Tactical Missile System (TMS), Medium Unmanned Aircraft Systems (MUAS), and High Altitude Pseudo-Satellite Systems (HAPS). The company supplies UAS, TMS, unmanned ground vehicle, and related services primarily to organizations within the U.S. Department of Defense and to international allied governments. It also designs, engineers, tools, and manufactures unmanned aerial and aircraft systems, including airborne platforms, payloads and payload integration, ground control systems, and ground support equipment and other items and services related to unmanned aircraft systems. In addition, the company offers small UAS products, including spare equipment, alternative payload modules, batteries, chargers, repair services, and customer support, as well as multiple aircraft, hand-held ground control system, and spare parts and accessories. Further, it develops high-altitude pseudo-satellite UAS systems. The company was incorporated in 1971 and is headquartered in Arlington, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holland Charles RDirectorJul 07Sale84.204,001336,88456,998Jul 11 04:27 PM
Holland Charles RDirectorJul 06Sale82.612,001165,30360,999Jul 06 07:51 PM
Holland Charles RDirectorJul 05Sale80.873,001242,69163,000Jul 06 07:51 PM
Nawabi WahidPresident and CEOJun 29Option Exercise0.006,695075,764Jul 01 05:49 PM
Brown Melissa AnnVP, Gen. Counsel, Corp. SecJun 29Option Exercise0.00984012,321Jul 01 05:50 PM
CompanyQuickLogic Corporation
Market Cap80.01MEPS (ttm)-0.38
P/E-EPS this Y49.70%
Forward P/E38.83EPS next Y328.60%
PEG-EPS past 5Y32.50%
P/S4.94EPS next 5Y20.00%
P/B7.91EPS Q/Q76.50%
Dividend-Sales Q/Q55.20%
Insider Own2.40%Inst Own21.00%
Insider Trans-9.70%Inst Trans0.15%
Short Float3.29%EarningsAug 16/a
Analyst Recom1.70Target Price11.00
Avg Volume67.85K52W Range4.25 - 9.21
Sep-08-22 08:33AMQuickLogic Awarded a $6.9 Million Base Contract to Develop Strategic Radiation Hardened FPGA Technology PR Newswire
Aug-30-22 09:00AMQuickLogic to Participate in the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
Aug-16-22 05:25PMQuickLogic (QUIK) Reports Break-Even Earnings for Q2 Zacks
Aug-16-22 04:05PMQuickLogic Reports Fiscal 2022 Second Quarter Results PR Newswire
Aug-10-22 09:00AMQuickLogic to Participate in the Rosenblatt Virtual Technology Summit PR Newswire
Jul-27-22 09:01AMQuickLogic (NASDAQ:QUIK) shareholders have endured a 61% loss from investing in the stock five years ago Simply Wall St.
Jul-27-22 09:00AMQuickLogic to Report Second Quarter Fiscal Year 2022 Financial Results on Tuesday, August 16, 2022 PR Newswire
Jul-20-22 08:34AMaiSensing Deploys Highly Successful End-Point AI Vibration Sensor Using SensiML Analytics Toolkit and QuickLogic EOS S3 PR Newswire
Jun-16-22 08:35AMQuickLogic and eTopus Announce Disaggregated, Flexible eFPGA Chiplet Template PR Newswire
Jun-08-22 08:35AMSensiML to Participate in Upcoming Industry Conferences PR Newswire
QuickLogic Corporation, a semiconductor company, develops semiconductor platforms and intellectual property solutions for smartphones, wearable, hearable, tablets, and the Internet-of-Things devices. It also provides flexible sensor processing solutions, ultra-low power display bridges, ultra-low power field programmable gate arrays (FPGAs); and analytics toolkit, an end-to-end software suite that offers processes for developing pattern matching sensor algorithms using machine learning technology, as well as programming hardware and design software solutions. The company's products include pASIC 3, QuickRAM, QuickPCI, EOS, QuickAI, SensiML Analytics Studio, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II, as well as silicon platforms, IP cores, software drivers, firmware, and application software. It delivers its solutions through ultra-low power customer programmable System on Chip (SoC) semiconductor solutions, embedded software, and algorithm solutions for always-on voice and sensor processing, and enhanced visual experiences. In addition, the company licenses FPGA technology for use in other semiconductor companies SoCs. It markets and sells its products to original equipment manufacturers and original design manufacturers through a network of sales managers and distributors in North America, Europe, and the Asia Pacific. QuickLogic Corporation was founded in 1988 and is headquartered in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nader EliasCFO, SVP FINANCEAug 15Sale8.261,87615,4962,673Aug 16 12:02 PM
Nader EliasCFO, SVP FINANCEAug 10Option Exercise0.002,80404,549Aug 11 03:56 PM
Faith Brian CPRESIDENT AND CEOJul 26Sale7.7116,395126,478135,339Jul 27 01:02 PM
SAXE TIMOTHYSR. VP AND CTOJul 15Option Exercise0.0021,331092,947Jul 19 04:40 PM
TAUSS GARY HDirectorJul 15Option Exercise0.003,716014,315Jul 19 04:39 PM
CompanyEve Holding, Inc.
IndustryAerospace & Defense
Market Cap1.66BEPS (ttm)0.07
P/E83.24EPS this Y185.50%
Forward P/E-EPS next Y-29.00%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.93EPS Q/Q26.20%
Dividend-Sales Q/Q-
Insider Own90.40%Inst Own0.50%
Insider Trans0.00%Inst Trans-94.00%
Short Float2.23%EarningsAug 04/b
Analyst Recom2.00Target Price9.00
Avg Volume87.08K52W Range5.30 - 11.84
Sep-08-22 07:00AMUnited to Invest $15 Million in Flying-Taxi Maker Backed by Embraer The Wall Street Journal
Sep-08-22 07:00AMUnited Invests Another $15 Million in Electric Flying Taxi Market with Eve PR Newswire
Aug-31-22 08:00AMEve To Host Panel At Deutsche Bank Technology Conference Panel On Urban Air Mobility PR Newswire
Aug-23-22 07:00AMEve Announces First North American Urban Air Mobility Simulation in Chicago PR Newswire
Aug-09-22 08:26AMCompanies Like Eve Holding (NYSE:EVEX) Are In A Position To Invest In Growth Simply Wall St.
Aug-04-22 07:45AMEve Holding, Inc. Reports Second Quarter 2022 Results PR Newswire
Jul-28-22 10:33PMAir taxi developer Archer Aviation's stock soared 20% after a positive analyst report American City Business Journals
Jul-20-22 08:52AMEve Holding, Inc. to Report Second Quarter 2022 Results PR Newswire
Jul-19-22 10:56AMEve announces a Letter of Intent (LOI) for up to 150 eVTOLs from partnership between Embraer and BAE Systems PR Newswire
Jul-18-22 08:46AMEve announces Halo Aviation as the launch customer for its Urban Air Traffic Management solution PR Newswire
Eve Holding, Inc. develops urban air mobility solutions. It is involved in the design and production of eVTOLs; provision of eVTOL service and support capabilities, including material services, maintenance, technical support, training, ground handling, and data services; and development of urban air traffic management systems. The company is based in Melbourne, Florida.
CompanyLifeStance Health Group, Inc.
IndustryMedical Care Facilities
Market Cap2.78BEPS (ttm)-1.03
P/E-EPS this Y-26.00%
Forward P/E-EPS next Y72.50%
PEG-EPS past 5Y-
P/S3.58EPS next 5Y-
P/B1.76EPS Q/Q13.00%
Dividend-Sales Q/Q30.50%
Insider Own13.50%Inst Own83.90%
Insider Trans-1.81%Inst Trans1.26%
Short Float2.69%EarningsAug 09/a
Analyst Recom2.30Target Price8.80
Avg Volume665.68K52W Range4.77 - 16.50
Sep-08-22 09:00AMLifeStance Health Appoints Ken Burdick as CEO and Chairman; Founding CEO and Chairman Michael Lester Retires PR Newswire
Aug-30-22 04:10PMLifeStance to Participate in the Morgan Stanley Global Healthcare Conference GlobeNewswire
Aug-15-22 08:34AMLifeStance Health Group, Inc. (NASDAQ:LFST) Shares Could Be 37% Below Their Intrinsic Value Estimate Simply Wall St.
Aug-10-22 12:30AMLifeStance Health Group, Inc. (LFST) Q2 2022 Earnings Call Transcript Motley Fool
Aug-09-22 07:45PMLifeStance Health Group (LFST) Reports Q2 Loss, Lags Revenue Estimates Zacks
Aug-09-22 04:10PMLifeStance Reports Second Quarter 2022 Results GlobeNewswire
Jul-19-22 05:00PMLifeStance to Host Second Quarter 2022 Earnings Conference Call on August 9, 2022 GlobeNewswire
Jul-08-22 08:13AMLifeStance Health (LFST) Soars 6.2%: Is Further Upside Left in the Stock? Zacks
Jul-07-22 09:00AMGwen Booth Named Executive Director of LifeStance Health Foundation PR Newswire
Jul-04-22 02:53PMInvestors are selling off LifeStance Health Group (NASDAQ:LFST), lack of profits no doubt contribute to shareholders one-year loss Simply Wall St.
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gouk WarrenChief Administrative OfficerAug 23Sale7.0217,226120,9276,144,748Aug 24 05:15 PM
Gouk WarrenChief Administrative OfficerAug 15Sale7.8517,226135,2246,161,974Aug 16 04:00 PM
Gouk WarrenChief Administrative OfficerAug 08Sale7.3017,226125,7506,179,200Aug 10 05:00 PM
Gouk WarrenChief Administrative OfficerAug 03Sale7.0068,904482,3286,196,426Aug 05 04:15 PM
Lester Michael K.President and CEOJun 13Sale5.33328,6151,751,51823,148,931Jun 14 04:40 PM